Ab initio Investigation of Adsorption Characteristics of Bisphosphonates on Hydroxyapatite (001) Surface
Source abstract
Abstract
Structures of some bisphosphonates (clodronate, etidronate, pamidronate, alendronate, risedronate, zoledronate) were relaxed and analyzed by DFT method. By comparing their adsorption energies onto hydroxyapatite (001) surface with and without solvation effect and analyzing HOMOs (highest occupied molecular orbitals), LUMOs (lowest unoccupied molecular orbitals), and DOS (density of states) of bisphosphonates and hydroxyapatite (001) surface, it can be shown that the binding affinity of alkyl N-BPs (bisphosphonates containing nitrogen atom in an alkyl chain) is the highest among bisphosphonates, and the adsorption energy of bisphosphonates onto hydroxyapatite (001) surface is the main factor to determine the binding affinity of bisphosphoates with bone material.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Bone health and treatments · Boron Compounds in Chemistry · Chemical Synthesis and Characterization
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (54)
Show source-provided references
1. Bartl R, Frisch B, von Tresckow E, Bartl C (2007) Bisphosphonates in medical practice. Springer, Berlin10.1007/978-3-540-69870-8 ↗
2. Ebetino FH, Hogan A-ML, Sun S, Tsoumpra MK, Duan X, Triftt JT, Kwaasi AA, Dunford JE, Barnett BL, Oppermann U, Lundy MW, Boyde A, Kashemirov BA, McKenna CE, Russell RGG (2011) The relationship between the chemistry and biological activity of the bisphosphonates. Bone 49:20–3310.1016/j.bone.2011.03.774 ↗
3. Coxon FP, Thompson K, Rogers MJ (2006) Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol 6:307–31210.1016/j.coph.2006.03.005 ↗
4. Russell RGG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733–75910.1007/s00198-007-0540-8 ↗
5. Russell RGG (2011) Bisphosphonates: the first 40 years. Bone 49:2–1910.1016/j.bone.2011.04.022 ↗
6. Volkert WA, Hoffman TJ (1999) Therapeutic radiopharmaceuticals. Chem Rev 99:2269–229210.1021/cr9804386 ↗
7. Kontecka EG, Jezierska J, Lecouvey M, Leroux Y, Kozlowski H (2002) Bisphosphonate chelating agents: coordination ability of 1-phenyl-1-hydroxymethylene bisphosphonate towards Cu2+ ions. J Inorg Biochem 89(1–2):13–1710.1016/S0162-0134(01)00412-3 ↗
8. Fleich H (1998) Bisphosphonates: mechanisms of action. Endocr Rev 19(1):80–10010.1210/edrv.19.1.0325 ↗
9. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88(12 Suppl):2961–297810.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L ↗
10. Roelofs AJ, Thompson K, Gordon S, Rogers M (2006) Molecular mechanisms of action of bisphosphonates: current status. J Clin Cancer Res 12:6222–623010.1158/1078-0432.CCR-06-0843 ↗
11. Russell RG, Muhlbauer RC, Bisaz S, Williams DA, Fleisch H (1970) The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats. Calcif Tissue Res 6:183–9610.1007/BF02196199 ↗
12. Fleisch HA, Russell RG, Bisaz S, Muhlbauer RC (1970) The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro Williams DA, on aortic, and kidney calcification in vivo. Eur J Clin Invest 1:12–1810.1111/j.1365-2362.1970.tb00591.x ↗
13. Ebetino FH, Francis MD, Rogers MJ et al (1998) Mechanisms of action of etidronate and other bisphosphonates. Rev Contemp Pharmacother 9:233–43
14. Ebetino FH, Dansereau SM (1995) Bisphosphonates antiresorptive structure-activity relationship. In: Bijvoet OLM, Fleisch HA, Canfield RE, Russell RGG (eds) Bisphosphonate on bones. Elsevier, Amsterdam, pp 139–153
15. Luckman SP, Coxon FP, Ebetino FH et al (1998) Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in j774 macrophages. J Bone Miner Res 13(11):1668–7810.1359/jbmr.1998.13.11.1668 ↗
16. Benedict (1995) The physical chemistry of the diphosphonates-its relationship to their medical activity. In Donath A and Courvoiser B (eds), Symposium CEMO IV. Diphosphonates and bone, pages 1–19
17. Van Beek E, Lwik C, Que I et al (1996) Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group. J Bone Miner Res 11(10):1492–9710.1002/jbmr.5650111016 ↗
18. Papapoulos SE, Hoekman K, Lowik CWGM, Vermeij P, Bijvoet OLM (1988) Application of an in vitro model and a clinical proto col in the assessment of the potency of a new bisphosphonate. J Bone Miner Res 4:775–8110.1002/jbmr.5650040518 ↗
19. Goa KL, Balfour JA (1998) Risedronate. Drugs Aging 13:83–9110.2165/00002512-199813010-00008 ↗
20. Green JR, Mueller K, Jaeggi KA (1994) Preclinical pharmacology of cgp 42 446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 9:745–5110.1002/jbmr.5650090521 ↗
21. Oldfield E (2010) Targeting isoprenoid biosynthesis for drug discovery: bench to bedside. Acc Chem Res 43:1216–2610.1021/ar100026v ↗
22. Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA et al (2007) Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 1117:209–5710.1196/annals.1402.089 ↗
23. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:809–2210.1056/NEJMoa067312 ↗
24. Owens G, Jackson R (2007) An integrated approach: bisphosphonate management for the treatment of osteoporosis Lewiecki EM. Am J Manag Care 13(Suppl 1):S290–308
25. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W et al (2006) Novel insights into actions of bisphosphonates: differences in interactions with hydroxyapatite on bone. Bone 38:617–2710.1016/j.bone.2005.05.003 ↗
26. Lawson MA, Xia Z, Barnett BL, Triffitt JT, Phipps RJ, Dunford JE, Locklin RM, Ebetino FH, Russell RGG (2010) Differences between bisphosphonates in binding affinities for hydroxyapatite. J Biomed Mater Res B Appl Biomater 92:149–5510.1002/jbm.b.31500 ↗
27. Leu CT, Luegmayr E, Freedman LP, Rodan GA, Reszka AA (2006) Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy. Bone 38:628–3610.1016/j.bone.2005.07.023 ↗
28. Jahnke W, Henry C (2010) An in vitro assay to measure targeted drug delivery to bone mineral. Chem Med Chem 5:770–610.1002/cmdc.201000016 ↗
29. Mukherjee S, Song Y, Oldfield E (2008) Nmr investigations of the static and dynamic structures of bisphosphonates on human bone: a molecular model. J Am Chem Soc 130:1264–7310.1021/ja0759949 ↗
30. Mukherjee S, Huang C, Guerra F, Wang K, Oldfield E (2008) Thermodynamics of bisphosphonates binding to human bone: a two-site model. J Am Chem Soc 131:8374–510.1021/ja902895p ↗
31. Duan X, Xia Z, Zhang H, Quijano M, Dobson RLM, Triffit JT et al (2010) The effects of ph on the relative bone mineral-binding affinities of bisphosphonates determined by hydroxyapatite-column chromatography. J Bone Miner Res 25(Suppl 1):S347
32. Lawson MA, Triffin JT, Ebetino FH et al (2005) Potential bone mineral binding differences among bisphosphonates can be demonstrated by the use of hydroxyapatite column chromatography [abstract]. J Bone Miner Res 20(Suppl 1):S396
33. Ebetino FH, Barnett BL, Russell RGG (2005) A computational model delineates differences in hydroxyapatite binding affinities of bisphosphonate [abstract]. J Bone Miner Res 20(Suppl 1):S259
34. Duarte LF, Teixeira FC, Fausto R (2010) Molecular modeling of the interaction of novel hydroxyl- and aminobisphosphonates with hydroxyapatite. ARKIVOC, (v):117
35. Zhu W, Wu P (2004) Surface energetics of hydroxyapatite: a dft study. Chem Phys Lett 396:38–4210.1016/j.cplett.2004.08.006 ↗
36. Barrios NA (2010) A Computational Investigation of the Interaction of the Collagen Molecule with Hydroxyapatite. PhD thesis, Department of Chemistry, University College London
37. Corno Marta, Rimola Albert, Bolis Vera, Ugliengo Piero (2010) Hydroxyapatite as a key biomaterial: quantum-mechanical simulation of its surface in interaction with biomolecules. Phys Chem Chem Phys 12:6309–632910.1039/c002146f ↗
38. Canepa Pieremanuele, Chiatti Fabio, Corno Marta, Sakhmo Yuriy, Marta Giamario, Ugliengo Piero (2011) Affinity of hydroxyapatite (001) and (010) surfaces to formic and alendronic acids: a quantum-mechanical and infrared study. Phys Chem Chem Phys 13:1099–111110.1039/C0CP01143F ↗
39. David Fernandez, Joaquin Ortega-Castro, Juan Fran (2017) Theoretical study of the deposition and adsorption of bisphosphonates on the 001 hydroxyapatite surface: Implications in the pathological crystallization inhibition and the bone antiresorptive action. Appl Surf Sci 392:2004–2014
40. Ri MH, Yu CJ, Jang YM, Kim SU (2016) Ab initio investigation of the adsorption of zoledronic acid molecule on hydroxyapatite (001) surface: an atomistic insight of bone protection. J Mat Sci 51:3125–313510.1007/s10853-015-9622-8 ↗
41. Kirkpatrick S, Gelatt CD, Vecchi MP (1983) Optimization by simulated annealing. Science 220:671–68010.1126/science.220.4598.671 ↗
42. Gale JD, Rohl AL (2003) The general utility lattice program (gulp). Mol Simul 29:291–34110.1080/0892702031000104887 ↗
43. Mayo SL, Olafson BD, Goddard WA (1990) Dreiding: a generic forcefield. J Phys Chem 94:8897–890910.1021/j100389a010 ↗
44. Rappe AK, Goddard WA (1991) Charge equilibration for molecular dynamics simulations. J Phys Chem 95(8):3358–336310.1021/j100161a070 ↗
45. Soler JM, Artacho E, Gale JD, García A, Junquera J, Ordejón P, Sánchez-Portal D (2002) The siesta method for ab initio order-n materials simulation. J Phys Condens Matter 14:2745–277910.1088/0953-8984/14/11/302 ↗
46. Hohenberg P, Kohn W (1964) Inhomogeneous electron gas. Phys Rev 136:B864–87110.1103/PhysRev.136.B864 ↗
47. Kohn W, Sham LJ (1965) Self-consistent equations including exchange and correlation effects. Phys Rev 140:A1133–113810.1103/PhysRev.140.A1133 ↗
48. Becke AD (1988) Density-functional exchange-energy approximation with correct asymptotic behavior. Phys Rev A 38:3098–310010.1103/PhysRevA.38.3098 ↗
49. Lee C, Yang W, Parr RG (1988) Development of the colle-salvetti correlation-energy formula into a functional of the electron density. Phys Rev B 37:785–78910.1103/PhysRevB.37.785 ↗
50. Troullier N, Martins JL (1991) Efficient pseudopotentials for plane-wave calculations. Phys Rev B 43:1993–200610.1103/PhysRevB.43.1993 ↗
51. Perdew JP, Zunger A (1981) Self-interaction correction to density-functional approximations for many-electron systems. Phys Rev B 23:5048–507910.1103/PhysRevB.23.5048 ↗
52. Almora-Barrios N, Austen K, de Leeuw N (2009) A density functional theory study of the binding of glycine, proline and hydroxyproline to the hydroxyapatite (0001) and (0110) surfaces. Langmuir 25:5018–502510.1021/la803842g ↗
53. Wierzbicki A, Cheung HS (2000) Molecular modeling of inhibition of hydroxyapatite by phosphocitrate. J Mol Struct Theochem 529:73–8210.1016/S0166-1280(00)00534-0 ↗
54. de leeuw NH (2004) A computer modelling study of the uptake and segregation of fluoride ions at the hydrated hydroxyapatite (0001) surface: introducing a $$\text{ ca }10$$ ca 10 ( $$\text{ po }_4$$ po 4 ) $$_6\text{(oh) }_2$$ 6 (oh) 2 potential model. Phys Chem Chem Phys 6:1860–186610.1039/B313242K ↗